SRPT Stock Analysis: Buy, Sell, or Hold?
SRPT - Sarepta Therapeutics,, Inc. Common Stock
$19.08
0.24 (1.27%)
▲
5d:
-8.27%
30d:
-12.2%
90d:
+9.66%
HOLD
LOW Confidence
Analysis Updated: May 13, 2026 12:00 AM ET
Earnings: May 06, 2026
0d
Smart Money Accumulation
SRPT is down 18.2% this week, but smart money is accumulating calls. Top strike: $22.5 2026-06-18 with 1,973 OI. Call ratio: 63% View Scanner →
Strength: 10.0/10
Get Alerted When SRPT Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
12 traders called SRPT this week
64% bullish • 5 bearish
64% bullish • 5 bearish
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: SRPT shows mixed signals. Fine to hold existing positions. Not urgent to buy or sell.
📊 HOLD: SRPT shows mixed signals. Fine to hold existing positions. Not urgent to buy or sell.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$6.90
Based on -17.6% avg growth
INTRINSIC VALUE TODAY
$4.28
Trading above historical range
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 6.8x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: SRPT is currently trading at $19.08, which is considered oversold relative to its 30-day fair value range of $20.13 to $22.24. The stock's valuation (Forward PE: 6.4) is in line with its historical norms (6.8). Remarkably, the market is currently pricing in an annual earnings decline of 2.0% over the next few years. This pessimistic expectation contrasts with the company's recent 2663.8% earnings growth, suggesting potential undervaluation if the company simply maintains stability.
Technical Outlook: Technically, SRPT is in a strong downtrend. The price is currently testing key support at $18.65. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $22.00 (+16.8%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, SRPT is in a strong downtrend. The price is currently testing key support at $18.65. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $22.00 (+16.8%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$20.13 -
$22.24
Company Quality Score
53/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
77.1%
Protect Your Profits
Holding SRPT? Use our AI-powered strategies to protect your downside while keeping your long-term position.
View Profit Protection PlanAll Signals
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Mixed technical signals (40/100)
- BULLISH: High volume confirmation
- BULLISH: Trading below Wall St target ($22.00)
- CAUTION: Recommendation downgraded due to -8.3% 5-day decline
Trading Range Analysis
30-Day Trading Range
$20.13 -
$22.24
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$18.65
Resistance Level
$23.49
Current Trend
Strong Downtrend
Technical data as of
May 13, 2026
Fundamental Context
Forward P/E (Next Year Est.)
6.44
Wall Street Target
$22.00
(+16.8%)
Revenue Growth (YoY)
-1.9%
Earnings Growth (YoY)
2663.8%
Profit Margin
3.0%
Valuation Discount vs History
-2.0% cheaper
PE vs Historical
6.4 vs 6.8
FAIR
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-2.0%
(market-implied from PE analysis)
1-Year Target
$18.46
(-2%)
2-Year Target
$18.09
(-4%)
3-Year Target
$17.73
(-6%)
3-Yr Target (if PE normalizes)
(PE: 6→7)
$18.73
(-1%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 22.0, Growth: -39.3%)
$47.03
(+150%)
Base:
(SPY PE: 6.4, Growth: -39.3%)
$13.73
(-27%)
Bear:
(PE: 5.5, Growth: -39.3%)
$11.67
(-38%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (6x PE), but valuation improves significantly next year (6x PE) as earnings recover.
Forward PE: 6.49 | Forward EPS (Implied): $2.90
Bull Case
$22.75
(+21%)
Analyst growth 15.0%, PE expands to 6.8
Base Case
$18.84
(0%)
Market implied 0.0%, PE stable at 6.5
Bear Case
$14.41
(-24%)
Severe decline -15.0%, PE contracts to 5.8
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 6.4 to 6.8
Stabilization Target:
$19.90
(+5.6%)
PE Expansion Potential:
+5.6%
Share & Embed Analysis
Last updated: May 14, 2026 10:47 AM ET
Data refreshes hourly during market hours. Next update: 11:47 AM
Data refreshes hourly during market hours. Next update: 11:47 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is SRPT showing a specific setup today?
Insider Activity (6 Months)
0
Buys
2
Sells
Net
INSIDERS SELLING
Recent Transactions
Stephen Mayo
SELL
7239 shares
2026-03-12
Ian Michael Estepan
SELL
13187 shares
2025-12-16
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
LEGN
Legend Biotech Corp |
STRONG BUY
22 analysts |
$57 | 59 HOLD |
|
RARE
Ultragenyx |
STRONG BUY
20 analysts |
$53 | 61 BUY |
|
JAZZ
Jazz Pharmaceuticals PLC |
STRONG BUY
18 analysts |
$242 | 66 BUY |
|
KYMR
Kymera Therapeutics Inc |
STRONG BUY
20 analysts |
$118 | 57 HOLD |
|
VKTX
Viking Therapeutics Inc |
STRONG BUY
19 analysts |
$92 | 50 HOLD |
Advanced SRPT Option Strategies
Professional options setups generated by AI based on today's SRPT price and gamma walls.
